Teleflex Secures Major Contract with Vizient for Central Venous Catheters
Thursday, Jan 9, 2025 6:38 am ET
3min read Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract by Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company. The agreement, effective starting August 1, 2022, covers the supply of Central Venous Access products, including Teleflex’s Arrow™ CVCs and Arterial Catheters.
This new agreement allows Vizient members to take advantage of special pricing and terms pre-negotiated by Vizient for Central Venous Access products. Teleflex, as the market leader in Central Venous Catheters (CVCs) with a market unit share of 60% in 2021 (IMS Data), is pleased to offer Vizient provider-customers one of the broadest portfolios of central access products available.
Teleflex’s Arrow™ Vascular Access Products are designed to equally benefit clinicians and patients, help protect against vascular access-related complications like infection, thrombosis, and tip malposition, and help clinicians follow independent third-party vascular access guidelines. The company’s Arrowg+ard Blue Plus™ CVCs feature broad-spectrum antimicrobial protection against fungi, gram-positive, and gram-negative bacteria, reducing Central Line-Associated Bloodstream Infections (CLABSI) by 67-100% (Rupp ME, Lisco SJ, Lipsett PA, et al., 2005; Lorente L, Lecuona M, Jimenez A, et al., 2014, 2016).
The contract includes access to Teleflex Arrowg+ard Blue Plus™ CVCs and Arrow™ ErgoPack™ Complete Systems. These solutions help healthcare systems comply with practice recommendations, standardize vascular access products across a healthcare system, maintain a high standard of patient care, and control costs and risks from infections (CDC Recommendations, SHEA Guidelines, INS Standards of Practice, and OSHA Bloodborne Pathogens Standard).
Teleflex, through its Arrow™ Catheters, has been at the forefront of vascular access innovation for more than four decades. The company’s commitment to quality, innovation, and customer satisfaction has positioned it as a trusted partner in the healthcare industry. This contract with Vizient further solidifies Teleflex’s market position and aligns with the company’s long-term growth strategy.
In conclusion, Teleflex’s contract with Vizient for the supply of Central Venous Access products is a significant milestone for the company. This agreement provides increased access to Teleflex’s products for a substantial portion of the nation’s acute care providers, further enhancing the company’s market share and revenue potential. As a leading provider of medical technologies, Teleflex continues to demonstrate its commitment to improving patient outcomes and driving innovation in the healthcare industry.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
